Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Cancer Vaccine Institute

2 abstracts

Abstract
A phase 2 study to evaluate efficacy and safety of PRGN-2009, a novel gorilla adenovirus-based immunotherapy, in combination with pembrolizumab versus pembrolizumab monotherapy in patients with recurrent or metastatic cervical cancer.
Org: Cancer Vaccine Institute, UW Medicine, Precigen, Inc.,
Abstract
A phase II study of concurrent WOKVAC vaccination with neoadjuvant chemotherapy and HER2-targeted monoclonal antibody therapy.
Org: University of Washington and Fred Hutchinson Cancer Research Centre, Cancer Vaccine Institute, University of Washington Medical Center,